ImmunoGen, Inc. Expands Pipeline of Targeted Anticancer Compounds
CAMBRIDGE, Mass.--ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, today announced that it has licensed the exclusive right to develop and …